clonoSEQ is now covered by Medicare for MCL patients.
It is the first Medicare-reimbursed MRD test for patients with MCL and is clinically available as a CLIA-validated LDT.

Cancer detection that's as determined as you are.

Mantle cell lymphoma (MCL) is typically an aggressive cancer,1 and treatment has come a long way in recent years. But to make the most of today’s therapies, your doctor needs advanced tools that can detect even the smallest traces of disease. This information can be critical to making important decisions about your care.2

clonoSEQ® (pronounced clo-no-seek) is an advanced test that measures the small number of cancer cells that may remain in your body during and after treatment. This is called measurable (or minimal) residual disease, also known as MRD.2

Learn about MRD

Often, MRD doesn’t cause any signs or symptoms, but its presence may be a signal that cancer is returning.2,3

When it comes to treating MCL, your doctor’s ability to detect and monitor these traces of disease may be important for making timely and informed decisions about your treatment plan.3-7

Learn more about MRD

See how clonoSEQ can inform your care

clonoSEQ monitors your MRD throughout your cancer journey.

MRD testing helps you and your doctor assess your response to treatment, measure your disease over time, and potentially detect early signs of returning cancer by assessing low levels of disease other tests may miss.3,7,8

Learn more about clonoSEQ

Understand your coverage and support options

Medicare and other major insurance providers cover clonoSEQ testing performed on blood and bone marrow samples from patients with multiple myeloma, DLBCL, CLL, ALL or MCL at multiple time points throughout treatment.

Adaptive Assist™ is our patient support program that’s tailored to your individual needs.

See how we can help

“The results of this test gave me my life back.”

— Karen, blood cancer patient
Hear from a real patient

This page is intended for a US-based audience.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory-developed test (LDT). To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.

References:

  1. Referenced with permission from the NCCN Guidelines for Patients®️ for Mantle Cell Lymphoma, 2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed January 16, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  2. clonoSEQ®. [technical summary]. Seattle, WA. Adaptive Biotechnologies; 2020.
  3. Epstein-Peterson Z, et al. Haematologica. August 31, 2023 [epub ahead of print]. doi: 10.3324/haematol.2023.282898
  1. Wang M, et al. J Clin Oncol. 2023;41(3):555–567.
  2. Phillips T, et al. Blood Adv. 2023;7(16):4518-4527.
  3. Kumar A, et al. Clin Lymphoma Myeloma Leuk. 2021;21(4):230-237.
  4. Rezazadeh A, et al. Clin Lymphoma Myeloma Leuk. 2023;2152-2650.
  5. Kumar A. Paper presented at: 65th ASH Annual Meeting and Exposition; December 9-12, 2023; San Diego, CA. Abstract 738.